Thermo Fisher Scientific Inc. $TMO Holdings Cut by C WorldWide Group Holding A S

C WorldWide Group Holding A S cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 90.5% in the 2nd quarter, Holdings Channel reports. The firm owned 56,477 shares of the medical research company’s stock after selling 535,065 shares during the quarter. Thermo Fisher Scientific comprises approximately 0.7% of C WorldWide Group Holding A S’s holdings, making the stock its 24th biggest position. C WorldWide Group Holding A S’s holdings in Thermo Fisher Scientific were worth $28,315,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TMO. Pinnacle Wealth Management Advisory Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 16.1% during the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,763 shares of the medical research company’s stock valued at $884,000 after acquiring an additional 245 shares during the period. Integrated Wealth Concepts LLC lifted its position in Thermo Fisher Scientific by 38.3% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 8,524 shares of the medical research company’s stock valued at $4,274,000 after purchasing an additional 2,361 shares during the last quarter. Community Bank N.A. boosted its stake in Thermo Fisher Scientific by 2.3% during the 2nd quarter. Community Bank N.A. now owns 5,912 shares of the medical research company’s stock valued at $2,964,000 after purchasing an additional 134 shares during the period. RFG Advisory LLC boosted its holdings in shares of Thermo Fisher Scientific by 35.7% in the second quarter. RFG Advisory LLC now owns 3,231 shares of the medical research company’s stock valued at $1,620,000 after acquiring an additional 850 shares in the last quarter. Finally, Ramsay Stattman Vela & Price Inc. increased its stake in Thermo Fisher Scientific by 1.2% in the 2nd quarter. Ramsay Stattman Vela & Price Inc. now owns 16,215 shares of the medical research company’s stock worth $8,130,000 after purchasing an additional 199 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.7%

TMO opened at $603.43 on Wednesday. The company has a fifty day moving average of $575.12 and a 200-day moving average of $516.59. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00. The stock has a market cap of $223.12 billion, a PE ratio of 32.46, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the company earned $4.28 EPS. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. CLSA assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 target price for the company. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a report on Wednesday, August 5th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Finally, Morgan Stanley upped their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $624.64.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.